February 18, 2026
1 min read

J&J fleshes out US investment plan, telegraphing $1B cell therapy plant and 500 new jobs in PA

With $55 billion earmarked to bolster its U.S. operations, Johnson & Johnson is the latest drugmaker to zero in on expansion plans that are aimed, at least in part, at abating the Trump administration’s pharmaceutical tariff threats.

Leave a Reply

Your email address will not be published.

Previous Story

Recipharm focuses footprint with sale of Israel API plant, new CDMO partnership

Next Story

How the supplement industry is bridging Ozempic’s nutrition gaps

Previous Story

Recipharm focuses footprint with sale of Israel API plant, new CDMO partnership

Next Story

How the supplement industry is bridging Ozempic’s nutrition gaps

Latest from Blog

ROFI Drives New Approach to Crop Nutrition

With input costs continuing to pressure farm budgets, some growers are making difficult decisions to reduce fertilizer application rates. While that strategy may ease upfront expenses, it is also accelerating a broader
Go toTop